Carbidopa Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg
Reference Brands: Generic formulations marketed under different names
Category:
Neurology
Carbidopa is available in Tablets
and strengths such as 25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Carbidopa is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Carbidopa can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Carbidopa, marketed under the brand name Lodosyn, is a medication primarily used in the management of Parkinson’s disease. It works by inhibiting the enzyme aromatic L-amino-acid decarboxylase (DOPA decarboxylase or DDC) in the peripheral tissues, which prevents the premature conversion of Levodopa to dopamine outside the brain. This inhibition allows a greater proportion of administered Levodopa to cross the blood–brain barrier and exert its therapeutic effect in the central nervous system, effectively improving the control of Parkinson’s disease symptoms such as tremor, rigidity, and bradykinesia.
By selectively targeting peripheral DDC, Carbidopa enhances the bioavailability of Levodopa while minimizing side effects related to peripheral dopamine accumulation, including nausea, vomiting, and cardiovascular issues. The medication is available in oral tablet form and is often used in combination with Levodopa for optimal therapeutic outcomes. Carbidopa’s ability to preserve Levodopa for central nervous system activity makes it an essential component in Parkinson’s disease therapy, supporting both motor function and quality of life for patients. Its predictable pharmacologic profile and compatibility with Levodopa make it a preferred agent in long-term Parkinson’s disease management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing